Skip to main content
Premium Trial:

Request an Annual Quote

Delphic Acquires Dx Business of iQur

NEW YORK (GenomeWeb News) – Pharmacogenomics test developer and specialty lab company Delphic has acquired the diagnostics business of iQur.

London-based iQur specializes in liver diagnostics and therapies. Delphic, which also is based in London, said in a statement that the acquisition would enable it to "leverage its capabilities and infrastructure to offer improved services in infectious diseases to the clinical and clinical trials markets, and to access the growing market for blood-borne virus screening."

iQur will continue to supply its ELF liver fibrosis test, which measures three serum markers that have been shown to correlate with the level of liver fibrosis, in partnership with Siemens.

iQur said that it would now focus on its vaccines program targeted as hepatitis, other infections, and cancer.

Financial terms of the acquisition were not disclosed.

Filed under

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.